Los Angeles Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Los Angeles Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-67,751	Closed	-$192K	–	2462
2025 Q4	$192K	Buy	67,751 +19,579	+41%	+$63.3K	﹤0.01%	1251
2025 Q3	$128K	Hold	48,172	–	–	﹤0.01%	1311
2025 Q2	$47.4K	Hold	48,172	–	–	﹤0.01%	1308
2025 Q1	$69.4K	Buy	+48,172	New	+$88.8K	﹤0.01%	1070
2021 Q2	–	Sell	-18,005	Closed	-$505K	–	1576
2021 Q1	$505K	Sell	18,005 -13,062	-42%	-$385K	﹤0.01%	1213
2020 Q4	$808K	Sell	31,067 -25	-0.1%	-$749	﹤0.01%	1026
2020 Q3	$1.16M	Hold	31,092	–	–	0.01%	768
2020 Q2	$1.59M	Sell	31,092 -225	-0.7%	-$9.41K	0.01%	684
2020 Q1	$987K	Sell	31,317 -9,068	-22%	-$479K	0.01%	712
2019 Q4	$2.41M	Sell	40,385 -6,305	-14%	-$283K	0.01%	596
2019 Q3	$1.71M	Buy	46,690 +19,170	+70%	+$759K	0.01%	671
2019 Q2	$1.28M	Buy	+27,520	New	+$1.29M	0.01%	763
2018 Q2	–	Sell	-3,160	Closed	-$229K	–	1448
2018 Q1	$229K	Buy	+3,160	New	+$232K	﹤0.01%	1236

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's ESPR Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 67,751 shares — an estimated $192K sold.

Los Angeles Capital Management first reported a position in ESPR in Q1 2018 and held it in 13 quarters. The position peaked at $2.41M in Q4 2019. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

Los Angeles Capital Management reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
Los Angeles Capital Management sold 67,751 Esperion Therapeutics shares in Q1 2026, an estimated $192K.
Los Angeles Capital Management first reported a position in Esperion Therapeutics in Q1 2018 and held it in 13 quarters.
Los Angeles Capital Management's Esperion Therapeutics position peaked at $2.41M in Q4 2019.
207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.